ZA200501921B - Novel injectable depot formulations - Google Patents
Novel injectable depot formulationsInfo
- Publication number
- ZA200501921B ZA200501921B ZA200501921A ZA200501921A ZA200501921B ZA 200501921 B ZA200501921 B ZA 200501921B ZA 200501921 A ZA200501921 A ZA 200501921A ZA 200501921 A ZA200501921 A ZA 200501921A ZA 200501921 B ZA200501921 B ZA 200501921B
- Authority
- ZA
- South Africa
- Prior art keywords
- injectable depot
- depot formulations
- novel injectable
- novel
- formulations
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42147302P | 2002-10-25 | 2002-10-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200501921B true ZA200501921B (en) | 2006-10-25 |
Family
ID=32176718
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200501921A ZA200501921B (en) | 2002-10-25 | 2005-03-07 | Novel injectable depot formulations |
Country Status (20)
Country | Link |
---|---|
US (1) | US20040138237A1 (nl) |
EP (1) | EP1575616A2 (nl) |
JP (1) | JP2006514923A (nl) |
KR (1) | KR20050055781A (nl) |
CN (1) | CN1849110A (nl) |
AR (1) | AR041722A1 (nl) |
AU (1) | AU2003267788A1 (nl) |
BR (1) | BR0315568A (nl) |
CA (1) | CA2503076A1 (nl) |
MX (1) | MXPA05002561A (nl) |
NL (1) | NL1024590C2 (nl) |
NO (1) | NO20052463L (nl) |
PA (1) | PA8586201A1 (nl) |
PE (1) | PE20040499A1 (nl) |
PL (1) | PL377679A1 (nl) |
RU (1) | RU2310450C2 (nl) |
TW (1) | TW200423941A (nl) |
UY (1) | UY28038A1 (nl) |
WO (1) | WO2004037289A2 (nl) |
ZA (1) | ZA200501921B (nl) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080113025A1 (en) * | 1998-11-02 | 2008-05-15 | Elan Pharma International Limited | Compositions comprising nanoparticulate naproxen and controlled release hydrocodone |
US20040001889A1 (en) | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
EP2959893A1 (en) | 2002-12-13 | 2015-12-30 | DURECT Corporation | Oral drug delivery system comprising high viscosity liquid carrier materials |
CA2537413A1 (en) * | 2003-09-02 | 2005-03-10 | Imran Ahmed | Sustained release dosage forms of ziprasidone |
PL1809329T3 (pl) | 2004-09-17 | 2012-08-31 | Durect Corp | Kompozycja znieczulająca zawierająca saib o przedłużonym uwalnianiu do stosowania miejscowego |
CA2598288A1 (en) * | 2005-03-03 | 2006-09-14 | Elan Pharma International Limited | Nanoparticulate compositions of heterocyclic amide derivatives |
US20080193542A1 (en) * | 2005-04-13 | 2008-08-14 | Pfizer Inc. | Injectable Deopot Formulations and Methods For Providing Sustained Release of Nanoparticle Compositions |
WO2006109177A1 (en) * | 2005-04-13 | 2006-10-19 | Pfizer Products Inc. | Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles |
US20080305161A1 (en) * | 2005-04-13 | 2008-12-11 | Pfizer Inc | Injectable depot formulations and methods for providing sustained release of nanoparticle compositions |
EA200800092A1 (ru) * | 2005-06-20 | 2008-06-30 | Элан Фарма Интернэшнл Лимитед | Композиции в виде наночастиц и с контролируемым высвобождением, включающие арил-гетероциклические соединения |
US20070027105A1 (en) | 2005-07-26 | 2007-02-01 | Alza Corporation | Peroxide removal from drug delivery vehicle |
US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
KR100908517B1 (ko) * | 2006-07-04 | 2009-07-20 | (주)아모레퍼시픽 | 호흡기계 약제 전달을 위한 서방형 다공성 미세입자 및 그제조 방법 |
US8337883B2 (en) | 2006-11-03 | 2012-12-25 | Durect Corporation | Transdermal delivery systems |
ES2562878T3 (es) | 2007-05-25 | 2016-03-08 | Indivior Uk Limited | Formulaciones de liberación sostenida de compuestos de risperidona |
WO2009088414A2 (en) | 2007-12-06 | 2009-07-16 | Durect Corporation | Oral pharmaceutical dosage forms |
JP5643195B2 (ja) * | 2008-06-16 | 2014-12-17 | デビオファーム インターナショナル ソシエテ アノニム | 濃縮オキサリプラチン溶液及びその調製方法 |
US20100260844A1 (en) | 2008-11-03 | 2010-10-14 | Scicinski Jan J | Oral pharmaceutical dosage forms |
GB2481017B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
CA2905131A1 (en) | 2013-03-15 | 2014-09-18 | Durect Corporation | Compositions with a rheological modifier to reduce dissolution variability |
GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
CN104688686A (zh) * | 2015-02-10 | 2015-06-10 | 万全万特制药江苏有限公司 | 一种含有齐拉西酮及其盐的脂肪乳注射剂 |
WO2018015915A1 (en) * | 2016-07-22 | 2018-01-25 | Cadila Healthcare Limited | A parenteral controlled release composition of an atypical antipsychotic agent |
GB2579707A (en) | 2018-10-15 | 2020-07-01 | Avent Inc | Compositions, systems, kits, and methods for neural ablation |
KR20220140711A (ko) | 2020-01-13 | 2022-10-18 | 듀렉트 코퍼레이션 | 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4029782A (en) * | 1975-04-28 | 1977-06-14 | Eli Lilly And Company | Cefazolin suspension for parenteral administration |
US4512986A (en) * | 1983-07-26 | 1985-04-23 | Research Triangle Institute | Progrestationally active steroids |
UA57734C2 (uk) * | 1996-05-07 | 2003-07-15 | Пфайзер Інк. | Комплекси включення арилгетероциклічних солей |
US6117949A (en) * | 1998-10-01 | 2000-09-12 | Macromed, Inc. | Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
PT1073432E (pt) * | 1998-04-14 | 2007-10-22 | Gen Hospital Corp | Utilização da d-alanina ou da d-serina para o tratamento da esquizofrenia |
DE60001649T2 (de) * | 1999-05-27 | 2003-08-21 | Pfizer Prod Inc | Ziprasidonsuspension |
US6753011B2 (en) * | 2000-01-14 | 2004-06-22 | Osmotica Corp | Combined diffusion/osmotic pumping drug delivery system |
EP1383445A4 (en) * | 2001-03-20 | 2005-04-13 | Cydex Inc | PREPARATION CONTAINING PROPOFOL AND SULFOALKYL ETHER CYCLODEXTRIN |
EP1269994A3 (en) * | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmaceutical compositions comprising drug and concentration-enhancing polymers |
-
2003
- 2003-10-13 WO PCT/IB2003/004576 patent/WO2004037289A2/en active Application Filing
- 2003-10-13 KR KR1020057006986A patent/KR20050055781A/ko not_active Application Discontinuation
- 2003-10-13 PL PL377679A patent/PL377679A1/pl not_active Application Discontinuation
- 2003-10-13 JP JP2004546264A patent/JP2006514923A/ja not_active Abandoned
- 2003-10-13 MX MXPA05002561A patent/MXPA05002561A/es unknown
- 2003-10-13 CN CNA2003801019024A patent/CN1849110A/zh active Pending
- 2003-10-13 AU AU2003267788A patent/AU2003267788A1/en not_active Abandoned
- 2003-10-13 EP EP03748483A patent/EP1575616A2/en not_active Withdrawn
- 2003-10-13 RU RU2005112207/15A patent/RU2310450C2/ru not_active IP Right Cessation
- 2003-10-13 BR BR0315568-4A patent/BR0315568A/pt not_active IP Right Cessation
- 2003-10-13 CA CA002503076A patent/CA2503076A1/en not_active Abandoned
- 2003-10-14 PA PA20038586201A patent/PA8586201A1/es unknown
- 2003-10-21 US US10/690,078 patent/US20040138237A1/en not_active Abandoned
- 2003-10-22 NL NL1024590A patent/NL1024590C2/nl not_active IP Right Cessation
- 2003-10-22 PE PE2003001071A patent/PE20040499A1/es not_active Application Discontinuation
- 2003-10-24 AR ARP030103894A patent/AR041722A1/es not_active Application Discontinuation
- 2003-10-24 TW TW092129568A patent/TW200423941A/zh unknown
- 2003-10-24 UY UY28038A patent/UY28038A1/es not_active Application Discontinuation
-
2005
- 2005-03-07 ZA ZA200501921A patent/ZA200501921B/xx unknown
- 2005-05-23 NO NO20052463A patent/NO20052463L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MXPA05002561A (es) | 2005-05-05 |
CA2503076A1 (en) | 2004-05-06 |
RU2310450C2 (ru) | 2007-11-20 |
PL377679A1 (pl) | 2006-02-06 |
AR041722A1 (es) | 2005-05-26 |
PE20040499A1 (es) | 2004-08-18 |
RU2005112207A (ru) | 2005-09-10 |
CN1849110A (zh) | 2006-10-18 |
NO20052463L (no) | 2005-05-23 |
EP1575616A2 (en) | 2005-09-21 |
NL1024590C2 (nl) | 2005-05-23 |
PA8586201A1 (es) | 2004-09-16 |
JP2006514923A (ja) | 2006-05-18 |
UY28038A1 (es) | 2004-05-31 |
BR0315568A (pt) | 2005-08-23 |
NL1024590A1 (nl) | 2004-04-27 |
US20040138237A1 (en) | 2004-07-15 |
WO2004037289A2 (en) | 2004-05-06 |
AU2003267788A1 (en) | 2004-05-13 |
WO2004037289A3 (en) | 2005-12-01 |
TW200423941A (en) | 2004-11-16 |
KR20050055781A (ko) | 2005-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200501921B (en) | Novel injectable depot formulations | |
IL161999A0 (en) | Injectable depot composition | |
GB0220467D0 (en) | Composition | |
GB0213638D0 (en) | Composition | |
HK1082412A1 (en) | Short duration depot formulations | |
GB0318894D0 (en) | Composition | |
GB0203421D0 (en) | Composition | |
GB0227244D0 (en) | Composition | |
GB0208608D0 (en) | Composition | |
GB0203296D0 (en) | Novel composition | |
GB0203280D0 (en) | Anti-glycolytic composition | |
GB0211924D0 (en) | Composition | |
GB0318152D0 (en) | Composition | |
GB0218241D0 (en) | Composition | |
GB0229808D0 (en) | Novel compositions | |
HK1082517A1 (en) | Oil-barrier composition | |
EP1495751A4 (en) | hair dye | |
GB0205786D0 (en) | Novel Composition | |
GB0229286D0 (en) | Composition | |
GB0228540D0 (en) | Novel compositions | |
AU2003216382A8 (en) | Idothyronine compositions | |
GB0213767D0 (en) | Composition | |
AU2003218497A8 (en) | Factorviia compositions | |
GB0203616D0 (en) | Composition | |
GB0201001D0 (en) | Novel composition |